Evidence map›Paper›PMID 39330026›Full record

ReviewCurrent oncology (Toronto, Ont.)2024

Cardiac Metastasis from Myxoid Liposarcoma Managed Successfully with Chemotherapy and Radiotherapy: Case Report and Review of the Literature.

Georgios M Stergiopoulos, Brittany L Siontis, Ivy A Petersen, Matthew T Houdek, Thanh P Ho, Scott H Okuno, Steven I Robinson

Abstract readCase ReportsReview
In one paragraph

Review in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Georgios M StergiopoulosDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Brittany L SiontisDepartment of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Ivy A PetersenDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Matthew T HoudekDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-0390-1018
Thanh P HoDepartment of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-7659-5766
Scott H OkunoDepartment of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-1297-6946
Steven I RobinsonDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiposarcoma, one of the most prevalent sarcoma histologies, is recognized for its tendency for extra-pulmonary metastases. While oligometastatic cardiac disease is rarely reported, it poses a unique challenge as oligometastatic sarcomas are often managed with surgical resection. CASE REPORT: We present a case of a 62-year-old man diagnosed with an oligometastatic myxoid liposarcoma (MLPS) to the heart 19 years after the primary tumor resection from the lower limb. The metastatic mass, situated in the pericardium adjacent and infiltrating the left ventricle, was not managed surgically but with a combination of chemotherapy and radiotherapy. The patient's disease remains stable to date, for more than 10 years. LITERATURE REVIEW: We conducted a review of the literature to determine the preferred management approach for solitary cardiac metastases of sarcomas. We also conducted an in-depth analysis focusing on reported cases of MLPS metastasizing to the heart, aiming to extract pertinent data regarding the patient characteristics and the corresponding management strategies.

conclusionsAlthough clinical diagnoses of solitary or oligometastatic cardiac metastases from sarcomas are infrequent, this case underscores the significance of aggressive management employing chemotherapy and radiotherapy for chemosensitive and radiosensitive sarcomas, especially when surgical removal is high-risk. Furthermore, it challenges the notion that surgery is the exclusive therapeutic option leading to long-term clinical benefit in patients with recurrent sarcomas.

Indexed as

Heart NeoplasmsLiposarcoma, MyxoidHumansMaleMiddle Agedcardiac metastasischemotherapyliposarcomamyxoid liposarcomapericardial metastasisradiotherapysarcoma

Identifiers

PMID39330026
PMCPMC11431419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.